Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 13/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12129672 | 1.00 | DHODH (0.58) | DHODHNR4A2NR1H4HTTRECQL | |
| SCHEMBL1336938 | 0.95 | DHODH (0.59) | DHODHNR4A2NR1H4HTTALDH1A1 | |
| SCHEMBL1335438 | 0.93 | DHODH (0.66) | DHODHNR4A2NR1H4RARARARB | |
| SCHEMBL1335669 | 0.91 | DHODH (0.69) | DHODH | |
| SCHEMBL1337021 | 0.88 | DHODH (0.67) | DHODHNR4A2HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL1337537 | 0.87 | DHODH (0.55) | DHODHNR4A2NR1H4ALDH1A1 | |
| SCHEMBL1336417 | 0.86 | DHODH (0.54) | DHODHNR4A2HTTSMN1; SMN2 | |
| SCHEMBL1337478 | 0.84 | DHODH (0.71) | DHODHNR4A2NR1H4RARARARB | |
| SCHEMBL1337629 | 0.84 | DHODH (0.60) | DHODHALDH1A1SMN1; SMN2 | |
| SCHEMBL1336975 | 0.84 | DHODH (0.79) | DHODHNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387362-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | RHIZEN PHARMACEUTICALS AG (CH) | 2022-12-08 | — | — | US | claimed |
| EP-4048251-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | Rhizen Pharmaceuticals AG (CH) | 2022-08-31 | — | — | EP | claimed |
| CN-114828842-A | Composition comprising DHODH inhibitor for the treatment of acute myeloid leukemia | 理森制药股份公司 | 2022-07-29 | — | — | CN | claimed |
| EP-4048251-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | Rhizen Pharmaceuticals AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| CN-114828842-A | Composition comprising DHODH inhibitor for the treatment of acute myeloid leukemia | 理森制药股份公司 | 2022-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387362-A1 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | DHODH, FLT3, IDH3A | DHODH 1/4885NR4A2 4065/4885NR1H4 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.